Last Update 05 Mar 26

Fair value Increased 14%

ARVN: 2026 Neurology Readouts And Cash Runway Will Balance Execution Risks

Narrative Update on Arvinas

The analyst price target for Arvinas has moved higher by $1.75, with analysts tying their updated views to refreshed post earnings models, a higher fair value estimate of $14.56, and anticipated 2026 data readouts for ARV-102 and other pipeline programs.

Analyst Commentary

Recent research updates show a cluster of higher price targets on Arvinas, with analysts revising their models after the latest quarterly report and company updates. The commentary focuses heavily on upcoming ARV-102 data, broader early stage pipeline milestones, and the company’s stated execution plans through 2026.

Bullish Takeaways

Bullish analysts have lifted their price targets into an approximate US$18 to US$20 range, reflecting updated models after the Q4 report and a higher fair value framework tied to pipeline progress.
Several research notes describe 2026 as a pivotal period, pointing to multiple planned data readouts across programs as potential catalysts for reassessing Arvinas’ longer term growth profile.
The reported year end 2025 cash balance of US$685.4m, with funding described as extending into the second half of 2028, is viewed as supportive for execution on clinical plans without near term financing assumptions.
Bullish analysts highlight upcoming ARV 102 data in Parkinson’s disease patients and potential trial initiations, such as a Phase Ib study in Progressive Supranuclear Palsy and the possibility of a registrational trial in 2026, as key events that could influence how the market values the pipeline.

Bearish Takeaways

Bearish analysts maintain Neutral ratings despite raising price targets, signaling that higher valuation estimates are balanced by caution around clinical risk and execution.
Some commentary explicitly states a wait and see stance, with analysts remaining on the sidelines until there is more clarity from ARV 102 and other Phase 1 programs, underscoring dependence on early stage data.
The emphasis on a “busy year of readouts” also highlights risk, as multiple clinical events concentrated into a relatively short period can introduce greater outcome uncertainty for both valuation and share price volatility.
Neutral views suggest that, while current cash is described as sufficient into 2028, the long path through Phase 1, potential registrational studies, and commercialization remains a key execution hurdle that could weigh on how aggressively some investors are willing to value Arvinas today.

What’s in the News

Arvinas named Randy Teel, Ph.D., as Chief Executive Officer effective February 12, 2026, moving him from his prior role as Chief Business Officer into the top role, while outgoing CEO John Houston, Ph.D., will stay on the Board and serve as a consultant (Key Developments).
Teel brings about 20 years of biopharmaceutical experience, including leading Arvinas’ 2018 IPO and overseeing corporate strategy, business development, investor relations and communications during the company’s shift to a public, clinical stage biotech (Key Developments).
Houston’s tenure as CEO included taking Arvinas public in 2018, progressing several investigational programs into the clinic, reporting first positive pivotal results for a PROTAC degrader, and raising more than US$2b through funding and partnerships (Key Developments).
Arvinas reported preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab at the ASH Annual Meeting 2025. A humanized high grade B-cell lymphoma model showed higher tumor growth inhibition for the combination than for either agent alone (Key Developments).
ARV-393 is in a Phase 1 trial in relapsed or refractory non Hodgkin lymphoma. Arvinas plans to share clinical data at a medical congress in 2026 and to add a glofitamab combination cohort for patients with diffuse large B cell lymphoma in that ongoing study (Key Developments).

Valuation Changes

Fair Value: increased from $12.81 to $14.56, a move of about $1.75 per share.
Discount Rate: edged up slightly from 6.96% to 6.98% in the updated model.
Revenue Growth: the assumed long term annual revenue change has shifted from a 20.64% decline to a 12.61% decline.
Net Profit Margin: revised modestly higher from 20.92% to 21.47%.
Future P/E: adjusted down from 24.97x to 24.17x, implying a slightly lower earnings multiple in the updated assumptions.

5 views

Key Takeaways

Advancements in targeted therapies and partnerships position Arvinas to capitalize on precision medicine trends and diversify future revenue streams.
Streamlined operations and supportive industry momentum enhance prospects for improved margins and faster approval timelines.
Cost-cutting measures, strategic pipeline shifts, and external commercialization uncertainties heighten risks to innovation, growth, and long-term profitability amid rising competition and industry headwinds.

Catalysts

About Arvinas

A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.What are the underlying business or industry changes driving this perspective?

Arvinas is positioned to benefit from a growing addressable market due to the rapid aging of the global population and the increasing prevalence of diseases like cancer and neurodegeneration, directly driving long-term potential for revenue growth as more patients seek innovative therapies.
The company's continued advancements in targeted and personalized therapies, specifically through its differentiated PROTAC platform and new clinical-stage assets such as ARV-102 (for Parkinson's/PSP), ARV-393 (BCL6 degrader), and ARV-806 (KRAS degrader), align with healthcare's shift toward precision medicine and expand opportunities for future high-margin product launches.
Solid progress and early validation in partnerships and licensing, as seen with Novartis and ongoing collaboration (or renegotiation) with Pfizer, offer the potential for substantial milestone payments and tiered royalties, thus strengthening future earnings and diversifying revenue streams.
Operational efficiencies executed via company-wide restructuring, strategic pipeline prioritization, and workforce reduction have significantly extended Arvinas' cash runway to 2028, improving the sustainability of R&D and positioning net margins for improvement even ahead of potential major product approvals.
Industry-wide momentum, including increased M&A and biopharma investment in targeted protein degradation and more supportive regulatory frameworks for breakthrough therapies, are expected to accelerate Arvinas' approval timelines, pipeline value realization, and drive overall earnings uplift as the sector re-rates innovators.

Arvinas Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Arvinas's revenue will decrease by 22.2% annually over the next 3 years.
Analysts are not forecasting that Arvinas will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Arvinas's profit margin will increase from -19.5% to the average US Pharmaceuticals industry of 23.2% in 3 years.
If Arvinas's profit margin were to converge on the industry average, you could expect earnings to reach $40.7 million (and earnings per share of $0.46) by about September 2028, up from $-72.6 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 49.1x on those 2028 earnings, up from -8.0x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 19.5x.
Analysts expect the number of shares outstanding to grow by 6.85% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Arvinas Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The recent restructuring resulted in cutting one-third of Arvinas' workforce, reprioritizing the pipeline, and reducing R&D expenses, reflecting a need to conserve cash that may constrain innovation and slow future program growth, potentially limiting long-term revenue and earnings expansion.
Uncertainty around vepdeg's commercialization path, including ongoing negotiations with Pfizer over development rights and no near-term plan for internal commercial infrastructure, raises the risk of delays or gaps in market launch, which could suppress anticipated revenue streams and earnings from their lead asset.
Heavy reliance on the unproven PROTAC platform and early-stage pipeline exposes Arvinas to significant R&D and regulatory risks; if pivotal clinical trials disappoint or timelines slip, this could result in prolonged negative net margins and increased cash burn.
Increasing competition in the targeted protein degradation and oncology space-including large pharma and other biotechs with advanced programs-may erode potential market share, threaten pricing power, and compress long-term revenue and profitability prospects.
Broader industry and policy trends such as global drug price regulation, rising cost of capital, and potential supply chain disruptions could heighten margin pressure and operational expenses, impacting long-term earnings and Arvinas' ability to sustain profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $18.444 for Arvinas based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $110.0, and the most bearish reporting a price target of just $7.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $175.3 million, earnings will come to $40.7 million, and it would be trading on a PE ratio of 49.1x, assuming you use a discount rate of 6.8%.
Given the current share price of $7.9, the analyst price target of $18.44 is 57.2% higher. Despite analysts expecting the underlying buisness to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Arvinas?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Precision Therapies Will Meet Demand Despite Clinical And Regulatory Risks